I’m inferring that Telix was given a heads up on MHRA decision timeline at their 2nd CHM meeting which could have been December 19/20. Telix did get a decision timeline obviously but whether that happened 12.19 or .20 is speculative. The York deal from 12.19 appears to have pre and post MHRA decision features at 5/50.
The Company's MAA to MHRA in the U.K. is in the active process of responses to questions received from MHRA. Nymox will update later in the cycle when appropriate
NWBO could do this but chooses not to. Single product OTC biotechs with no money only do this to bury bad news.